Scientific Sessions 2024  /  Late-Breaking Science: In-Depth with SUMMIT  /  In-Depth: SUMMIT: Tirzepatide for Patients With Heart Failure With Preserved Ejection Fraction and Obesity: the SUMMIT Trial
Logo

American Heart Association

  2
  0

Final ID:

In-Depth: SUMMIT: Tirzepatide for Patients With Heart Failure With Preserved Ejection Fraction and Obesity: the SUMMIT Trial

  • Packer, Milton  ( BAYLOR HEART AND VASCULAR INSTITUTE , Dallas , Texas , United States )
    • Author Disclosures:
    Milton Packer: DO have relevant financial relationships ; Consultant:89 bio:Past (completed) ; Consultant:Regeneron:Active (exists now) ; Consultant:Casana:Active (exists now) ; Consultant:Caladrius:Past (completed) ; Consultant:Boehringer Ingelheim:Past (completed) ; Consultant:Biopeutics:Active (exists now) ; Consultant:Altimmune:Active (exists now) ; Consultant:Attralus:Active (exists now) ; Consultant:Medtronic:Past (completed) ; Consultant:ARMGO:Active (exists now) ; Consultant:Ardelyx:Past (completed) ; Consultant:Lilly:Active (exists now) ; Consultant:Alnylam:Past (completed) ; Consultant:Imara:Past (completed) ; Consultant:Actavis:Past (completed)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Late-Breaking Science: In-Depth with SUMMIT

Saturday, 11/16/2024 , 03:15PM - 04:00PM

Late-Breaking Science In-Depth

More abstracts from these authors:
Blinded Withdrawal of Long-term Randomized Treatment with Empagliflozin or Placebo in Patients With Heart Failure

Packer Milton

Tirzepatide for Patients With Heart Failure With Preserved Ejection Fraction and Obesity: the SUMMIT Trial

Packer Milton

You have to be authorized to contact abstract author. Please, Login
Not Available